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Abstract
Introduction. Though the clinical signiﬁcance of testosterone deﬁciency is becoming increasingly apparent, its prevalence in
the general population remains unrecognised. A large web-based survey was undertaken over 3 years to study the scale of this
missed diagnosis.
Methods. An online questionnaire giving the symptoms characterising testosterone deﬁciency syndrome (Aging Male
Symptoms – AMS – scale) was set up on three web sites, together with questions about possible contributory factors.
Results. Of over 10,000 men, mainly from the UK and USA, who responded, 80% had moderate or severe scores likely to
beneﬁt from testosterone replacement therapy (TRT). The average age was 52, but with many in their 40s when the diagnosis
of ‘late onset hypogonadism’ is not generally considered. Other possible contributory factors to the high testosterone
deﬁciency scores reported were obesity (29%), alcohol (17.3%), testicular problems such as mumps orchitis (11.4%),
prostate problems (5.6%), urinary infection (5.2%) and diabetes 5.7%.
Conclusions. In this self-selected large international sample of men, there was a very high prevalence of scores which if
clinically relevant would warrant a therapeutic trial of testosterone treatment. This study suggests that there are large
numbers of men in the community whose testosterone deﬁciency is neither being diagnosed nor treated.
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Introduction
There is increasing recognition among doctors that
testosterone deﬁciency is a common and important
condition. As well as the key symptoms of loss of
energy, drive, libido and impaired erectile function,
there is often depression, memory loss and increased
irritability which can impair work, home and social
life.
This has also been causally linked to a wide range of
medical conditions [1] including metabolic syndrome
[2], diabetes [3], cardiovascular disease [4], osteo-
porosis [5], Alzheimer’s disease [6], depression [7],
frailty [8] and even premature death [9].
An even more important point is that not only are
there strong theoretical and epidemiological links to
these disorders, but testosterone treatment has also
been shown to be effective in the prevention and
treatment of many of them, especially diseases linked
with the recent epidemic of obesity such as metabolic
syndrome, Type 2 diabetes [10] and coronary heart
disease [11]. Also many of the conditions seen in
agingpopulationsworld-widewhichleadtofrailtyand
disability can be prevented by such treatment, making
it an effective form of preventive medicine. In view
of these beneﬁts, it was decided to undertake a web-
based survey of the prevalence of symptomatic
testosterone deﬁciency.
Methods
The standard English version of the 17-item Aging
Male Symptoms (AMS) scale [12], which is well
validated and widely used in research studies both to
detect symptoms which might suggest testosterone
deﬁciency syndrome (TDS) and monitor its treat-
ment [13,14], was made available on the web-site of
The Society for the Study of Androgen Deﬁciency
(SSAD – Andropause Society) and two other Centre
for Men’s Health web sites.
Additional questions were asked which were
thought would give information about factors which
might be related to androgen deﬁciency. As well as
age, these included questions about whether the
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testicular problems, prostate operation or inﬂamma-
tion, persistent urinary infection, vasectomy, recent
weight gain, diabetes or a high alcohol intake. For a
representative sub-sample, demographic data on city
and country of domicile and occupation were
available.
On completion of the full questionnaire, the
subject could immediately learn his total score and
rating according to the standards for this scale: 17–26
none, 27–36 little, 37–49 moderate, over 50 severe.
Given the high response rates to testosterone treat-
ment of scores at these levels, moderate and severe
scores were considered to represent testosterone
deﬁciency, and the advice given to consult a
physician.
Of the 13,861 respondents taking the online AMS
questionnaire between August 2007 and January
2010 (28 months), 10,896 gave permission for their
data to be analysed, and this was used in the study.
The information from the full questionnaire from
all three web-sites was down-loaded to an Excel
spreadsheet for analysis, using PASW 18 statistics
programme.
Results
With the exception of the respondents to the SSAD
site who gave a higher ‘Permission to use for analysis’
rate than either of the two commercial sites, i.e. was
more trusted, the data were very similar, from all
three web-sites, as shown by the mean age and total
AMS scores, as well as in the more detailed analyses,
two-thirds coming from the SSAD site (Table I).
The combined data from the three sites are therefore
used in this analysis.
Age and location of respondents
The age range of the respondents was 16–89 (mean
52 years), which is close to the mean age of patients
attending the Centre for Men’s health prior to
treatment, and recognised as the time when these
symptoms most commonly present as the ‘Andro-
pause’ or ‘Male Menopause’ (Figure 1). Though
symptoms of testosterone deﬁciency rarely present
below the age of 30, and can be recognised even in
the very elderly, the AMS scale, despite its name is
not signiﬁcantly age-related, unlike other commonly
used scales [15].
While there may have been a few respondents in
their 20s or earlier who were just experimenting with
the AMS questionnaire, it is remarkable that because
of spread of the normal distribution curve, 13% were
below the age of 40, and another 27% in their 40s,
i.e. 40% at ages when ‘Late Onset Hypogonadism’ is
generally not recognised as occurring. However it has
been found that the AMS scale can be used to
measure and compare the health-related quality of
life in those of less than 40 years of age on the basis of
similar European normative values [16]. The surpris-
ingly high prevalence of raised scores in the younger
age groups may be due to the increasing impact of
work stress in these age groups, which has been
shown to decrease testosterone synthesis [17,18] and
increase resistance to its action [19].
Seventy percent of respondents were from the UK,
10% from America, and the remainder from mainly
English speaking countries all over the World. There
was a wide scatter of occupations, and about 25%
were retired as would be expected from the age
distribution.
Severity of symptoms
As rated by their total AMS scores overall 30.3% had
‘moderate’ and another 49.7% ‘severe’ symptoms,
i.e. 80% having symptoms which gave them a high
probability of having TDS and which would warrant
a therapeutic trial (Figure 2). The proportion of
‘severe’ symptoms was slightly lower in the 30s and
less and 70s and over age groups, peaking in the 50s,
but this was balanced by raised ‘moderate’ scores in
the former groups.
Of the individual questions, as might be expected,
the three most highly rated questions were in the
sexual subscale of the AMS questionnaire, i.e.
decreases in ability and frequency of sexual activity,
morning erections and libido.
Table I. Analysis of data from three web-sites.
All data SSAD CMH MHC
Number with permission 108,96 6885 1001 3010
Source of data 100% 63% 9% 28%
% Refusing permission 22% 17% 32% 26%
Mean age 52.0 51.7 51.8 52.5
Total AMS score 48.6 48.9 50.3 52.4
Figure 1. Age distribution of web AMS respondents.
AMS web survey 11The prevalence of related factors is described in
the discussion section.
Discussion
This was not a random survey of the general
population, but was biased towards those searching
the web for an explanation of symptoms they thought
might be related to testosterone deﬁciency. Also
there could be over-representation of younger and
more computer literate age groups.
However, of this self-selected group of men who
answered an online version of the widely studied and
well validated AMS questionnaire, the results clearly
show that a very large number of men identify with
these classic symptoms of TDS. If they had been seen
in a clinic setting where other causes of these
symptoms could be excluded, as many as 80% might
warrant a therapeutic trial of testosterone treatment,
with a high probability of a positive response [20].
Related factors
In order of frequency, positive responses to the
additional questions following those of the AMS
scale (Figure 3) were as follows:
Recent weight gain (29% overall). This was noted most
frequently in the 40- and 50-years-old age groups.
Whether this could be considered as a cause or a
symptom is unclear, but this common complaint of
patients presenting for testosterone treatment can be
explained by the effect of testosterone deﬁciency
on the multipotent stem cell [21]. This promotes
differentiation from progenitor cells for muscle, bone
and epithelium, towards the pre-adipocyte and
adipocyte lineage. The resulting increase in adipocy-
tokines contributes to the greater prevalence of
metabolic syndrome, Type 2 diabetes, hypertension
and circulatory diseases seen in obese individuals
both in population surveys and in medical clinics.
This has caused the adipocyte to be termed ‘The axis
of evil’ [21].
Vasectomy (25% overall). The reported frequency of
this operation rose rapidly from 5% in the 30s age
group, to a peak of 34% in the 60s group, falling away
to the over 70s age group when vasectomy was less
common.
This is thought to be about twice the frequency of
this operation in the general population, and is a
signiﬁcant ﬁnding of this study. It is closely similar to
the 24% found in the UK Androgen Study (UKAS)
[22]. This could be because vasectomy is a marker
for the ‘High-T’ men who are more aware of symp-
toms when their testosterone drops later in life.
Alternatively, vasectomy could cause long-term
damage to the testosterone-producing capacity of
the testes many years after the operation for reasons
yet to be explained [22].
Alcohol (17.3% overall). This response to the ques-
tion about ‘High alcohol intake’ rose to a maximum
of 20% in the 40s, and is likely to have been an
underestimate because the population is modest
about reporting what it considers a reasonable
intake in relation to the proven reduction in
testosterone caused by alcohol, particularly with
binge drinking. Also, unlike the liver, the testis has
limited powers of regeneration, and high alcohol
intake, even many years previously, can cause lasting
damage to both spermatogenesis and testosterone
production.
‘Testicular problems and orchitis’ (11.4% overall). While
mumps orchitis has been described as the classic
example of an infection causing an endocrine dis-
order, other viral infections such as glandular fever
can also cause testicular damage and orchitis, as
can a variety of sexually transmitted diseases. The
reported prevalence of these testis-related conditions
was as might be expected highest in the youngest
group, but remained relatively constant at about 12%
at other ages.
Figure 2. Severity of AMS symptoms in different age groups.
Figure 3. Additional factors reported in the different age groups.
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urinary infections (5.2% overall). As well as being
stressful events likely to interfere with sexual activity,
and directly or indirectly suppress testosterone
production, benign prostatic enlargement has been
linked with higher oestrogen levels, which especially
in the obese individual can reduce androgen produc-
tion.
Prostate related problems and urinary infections
combined rose with age as would be expected to 17%
in the 60s and 35% in the over 70s.
Diabetes (5.7% overall). This rose from 2% in the
1930s to 10% in the 1970s. Together with obesity, it
is recognised as one of the major predisposing causes
of androgen deﬁciency [23]. Figures available for
Ireland show a population prevalence for all cases of
diabetes in 2005 of 5.4% in Northern Ireland and
4.7% in the Republic of Ireland. Taking into account
population change and the linear rise in obesity, these
ﬁgures are projected to rise to 6.3% in Northern
Ireland and 5.6% in the Republic of Ireland by 2015
[24]. Signiﬁcantly, low testosterone levels have
been found in up to 50% of diabetics, and more
importantly, the complications of this condition have
been reduced by testosterone treatment [25].
Symptomatic assessment
This level of symptoms at all ages is similar to that
seen in two studies carried out in urological clinics in
Germany where those men with moderate or severe
AMS scores were treated with two different testos-
terone preparations, testosterone injections and gel,
with equally good response rates [20,26] (Figure 4).
The uniform and sustained relief of these symp-
toms given by testosterone treatment has been
conﬁrmed by the experience over more than 15 years
in 1700 men in the UKAS treated predominantly on
the basis of their symptoms rather than androgen
levels [19].
Though the AMS was not originally developed as a
tool for diagnosing androgen deﬁciency, the majority
of the questions in it overlap with the typical
symptoms of TDS, which have been recognised
and consistent since they were ﬁrst described over 60
years ago by Dr. August Werner [27]. This ques-
tionnaire makes it possible to suspect TDS in the
clinical setting where other causes of these symptoms
can be excluded.
The paradox is that these characteristic symptoms
of testosterone deﬁciency are very poorly correlated
with total testosterone (TT) or other androgen levels
in the blood. This can be explained by the concept
of ‘androgen resistance’ [19]. As with insulin in
maturity onset diabetes mellitus, there can be both
insufﬁcient production and variable degrees of resis-
tance to the action of androgens operating at several
levels in the body simultaneously, with these factors
becoming progressively worse with aging, adverse
lifestyle, other disease processes, and a wide range
of medications. The mechanisms by which androgen
deﬁciency acts can be considered at ﬁve different
levels:
1. Impaired androgen synthesis or regulation.
2. Increased androgen binding.
3. Reduced tissue responsiveness.
4. Decreased androgen receptor activity.
5. Impaired transcription and translation.
This provides an explanation of why scores on a
range of questionnaires listing symptoms of testos-
terone deﬁciency consistently fail to predict low
androgen levels.
For example, a recent report on the AMS scale,
states that ‘the total AMS score was not signiﬁcantly
associated with TT’ [28]. Similarly, using three
questionnaires, including the AMS and Androgen
Deﬁciency in the Adult Male – St Louis (ADAM)
scales, no relationship was found between sympto-
matology and any of a battery of eight endocrine
assays, including TT and free testosterone (FT),
other than possibly age-related declines in dehydroe-
piandrosterone (DHEA) and insulin-like growth
factor 1 (IGF-1) [29]. Further, investigation of a
group of 81 Belgian men aged 53–66 (mean 59)
concluded ‘there was no correlation between
AMS (total and subscales) and testosterone levels
[30], while the same group in a study of 161 more
elderly men aged 74–89 (mean 78) also showed no
correlation between symptom scores and TT, FT, or
bioavailable testosterone (BT)’ [31].
One of the studies most clearly highlighting
the paradox dividing androgen deﬁciency symptom
scales and laboratory measures is that of Miwa
et al. in 2006, who found no correlation between
the total and psychological, somatic or sexual domain
scores of the AMS and serum levels of TT,
Figure 4. AMS Scores in normal population, and scores in patients
over the age of 40 in patients in a urological clinic before and after
3 months testosterone treatment [20].
AMS web survey 13FT, estradiol (E2), luteinizing hormone (LH),
follicle stimulating hormone (FSH), dehydroepian-
drosterone-sulphate (DHEAS), or growth hormone
(GH) [32].
Because of this high sensitivity but low speciﬁcity
of questionnaires to detect patients with low levels
of androgens, the complexity of factors involved in
androgen resistance, and the lack of validity of
androgen assays [33], it seems logical to adopt the
suggestion endorsed by Black et al. [34], which is
where typical symptoms or conditions known to be
related to androgen deﬁciency occur, that a 3-month
therapeutic trial of testosterone treatment be given,
providing it appears clinically justiﬁed.
This coincides with the emerging view that ‘An
emphasis and reliance on serum T alone hinders the
clinician’s ability to manage testosterone deﬁciency
syndromes (TDS)’ [29]. Low total testosterone is
just the tip of the iceberg of androgen deﬁciency, and
is a poor marker of the underlying larger mass of
symptoms and metabolic disturbances.
The high level of symptoms reported by these
men in the web survey highlights the ﬁndings in a
recently published study by one of the report’s
authors ‘Time for International Action on Treating
Testosterone Deﬁciency Symptoms’ [35]. This
gives world-wide data showing that testosterone
deﬁciency is the commonest hormonal disorder in
men, but the least commonly treated. In the UK
and all European countries, as well as Australia,
Japan and Russia, of the 20% of men over the age
of 50 who on a symptomatic basis can be rated as
deﬁcient in this hormone, less than 1% are being
treated. The USA treats about 8%. This makes
testosterone deﬁciency the most common endo-
crine disorder in men, and yet the least often
diagnosed and treated.
Diagnosis and treatment of testosterone deﬁciency
is economic and safe, and represents an important
part of the preventive medicine of the future. This
is not a condition which we can afford to leave
untreated for either the health or welfare of an aging
society.
In the light of the poor quality of life, energy,
vitality and sexual function of the testosterone
deﬁcient man, as well as the associated conditions
such as metabolic syndrome, diabetes, cardiovascular
disease, and osteoporosis, how long can the medical
community or health services afford to let men
continue to go without this treatment?
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